Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 6Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 135Small Cell Lung Carcinoma 51Lung Neoplasms 45Melanoma 15Carcinoma, Renal Cell 14Carcinoma, Transitional Cell 10Stomach Neoplasms 9Neoplasms 9Head and Neck Neoplasms 9Carcinoma, Hepatocellular 9Mesothelioma, Malignant 8Colorectal Neoplasms 8Urinary Bladder Neoplasms 7Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Breast Neoplasms 6Uterine Cervical Neoplasms 5Neoplasm Metastasis 5Kidney Neoplasms 5Carcinoma, Merkel Cell 5Thoracic Neoplasms 4Carcinoma, Neuroendocrine 4Small Cell Lung Cancer Extensive Stage 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Mesothelioma 3Lung Diseases 3Gastrointestinal Neoplasms 3Esophageal Neoplasms 3Brain Neoplasms 3

Interventions

pembrolizumab 1olaparib 1atezolizumab 1adagrasib 1Pemetrexed 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Solid Tumor × atezolizumab × Thoracic × Clear all
NCT04471415 2023-06-12

Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

Dracen Pharmaceuticals, Inc.

Phase 1/2 Terminated
61 enrolled
Other solid neoplasmThoracic

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡